Skip to content

Building a Leading Immunology Company

We selectively modulate key immune targets to create differentiated medicines.

About Us

We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders.

Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.

Our Programs

Developing novel and differentiated therapeutics that target both the innate and adaptive immune system.

TYK2

Inhibiting type I interferon and the Th1/Th17 axis for the treatment of psoriasis and other autoimmune diseases

About TYK2

A member of the JAK family, Tyrosine Kinase 2 (TYK2) regulates both innate and adaptive immunity by mediating type I interferon, IL-12 and IL-23 signaling. Selective inhibition of TYK2 without inhibition of other JAK family enzymes provides an optimal balance between reducing inflammation and preserving immune protection.

Learn More

S1P1R

Dampening the inflammatory response in IBD by sequestering lymphocytes in the lymph nodes

About the S1P1 Receptor

Sphingosine 1 phosphate (S1P) receptors are G-Protein Coupled Receptors involved in the modulation of numerous biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. S1P1 receptor (S1P1R) modulators sequester lymphocytes in the lymph nodes, resulting in fewer immune cells in the circulating blood to exacerbate inflammation.
Learn More

NLRP3

Targeting the inflammasome/IL-1β axis to break the inflammation feed-forward loop in autoinflammatory and autoimmune diseases

About NLRP3

NLRP3, the best-characterized inflammasome, is known to be activated by a range of non-infectious tissue damage signals associated with aging, physical inactivity and obesity. Its activation results in the production of inflammatory cytokines (IL-1β and IL-18), as well as a type of cell death called pyroptosis.

Learn More

cGAS

Targeting the cGAS/STING pathway for the treatment of type I interferon associated pathologies in autoinflammatory and autoimmune diseases

About cGAS

cGAS is the predominant sensor of abnormal double-stranded DNA in cells. The engagement of cGAS leads to the activation of STING. The cGAS/STING pathway stimulates the production of inflammatory cytokines, including type I interferon. While cGAS plays a role in host defense against invading pathogens, chronic activation by self-DNA can trigger systemic inflammation that exacerbates autoimmune disease progression.
Learn More

Gasdermin D

Inhibiting pyroptosis, a pro-inflammatory form of cell death, for the treatment of autoinflammatory diseases

About Gasdermin D

Pyroptosis, a form of cell death caused by lysis (cell membrane rupture), results in the rapid release of proinflammatory mediators. The pore-forming protein gasdermin D (GSDMD) is a central player in this cell death and deleterious inflammation feed-forward loop.



Learn More

Our Pipeline

Broad, clinical-stage immunology pipeline across diverse therapeutic areas.

Our Team

Highly experienced leaders in the discovery and development of immunology drugs.